Universal bilirubin screening for severe neonatal hyperbilirubinemia

Journal of Perinatology

Volumn 30, Issue SUPPL. 1, 2010, Pages

  Bhutani, V K ^a   Vilms, R J ^a   Hamerman Johnson, L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute bilirubin encephalopathy; hyperbilirubinemia; kernicterus; newborn jaundice; newborn screening; severe neonatal hyperbilirubinemia

Indexed keywords

BILIRUBIN;

BILIRUBIN BLOOD LEVEL; CLINICAL PATHWAY; CLINICAL TRIAL; CONFERENCE PAPER; DECISION SUPPORT SYSTEM; DIAGNOSTIC ACCURACY; DISEASE SURVEILLANCE; EARLY DIAGNOSIS; EXCHANGE BLOOD TRANSFUSION; FOLLOW UP; HEALTH CARE COST; HUMAN; KERNICTERUS; NEWBORN JAUNDICE; NEWBORN SCREENING; PHOTOTHERAPY; PREDICTION; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE;

BILIRUBIN; CRITICAL PATHWAYS; DECISION SUPPORT TECHNIQUES; EARLY DIAGNOSIS; EVIDENCE-BASED PRACTICE; GESTATIONAL AGE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERBILIRUBINEMIA, NEONATAL; INCIDENCE; INFANT, NEWBORN; KERNICTERUS; NEONATAL SCREENING; PARENTS; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE HEALTH SERVICES; RISK ASSESSMENT; SENTINEL SURVEILLANCE; UNITED STATES;

EID: 77957591871     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2010.98     Document Type: Conference Paper

References (49)

1. Subcommittee on Hyperbilirubinemia Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114:297-316.
2. Johnson L, Bhutani VK, Karp K, Sivieri EM, Shapiro SM. Clinical report from the pilot USA Kernicterus Registry (1992-2004). JPerinatol 2009;29(Suppl 1):S25-S45.
3. Van Praagh R. Diagnosis of kernicterus in the neonatal period. Pediatrics 1961;28:870-874.
4. Johnson LH, Brown AK, Bhutani VK. System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr 2002;140:396-403.
5. Bhutani VK, Johnson L, Keren R. Acute bilirubin encephalopathy... before it is too late. Contemporary Pediatrics 2005;22(5):54-74.
6. Johnson L, Brown AK, Bhutani VK. BIND-A clinical score for bilirubin induced neurologic dysfunction in newborns. Pediatrics 104;746:1999.
7. Shapiro SM. Definition of the clinical spectrum of kernicterus and bilirubin-1 induced neurologic dysfunction (BIND). JPerinatol 2005;25(1):54-59.
8. Shapiro SM, Bhutani VK, Johnson L. Hyperbilirubinemia and kernicterus. Clin Perinatol 2006;33(2):387-410.
9. Wennberg RP, Ahlfors CE, Bhutani VK, Johnson LH, Shapiro SM. Toward understanding kernicterus: a challenge to improve the management of jaundiced newborns. Pediatrics 2006;117:474-485.
10. McDonagh AF, Vreman HJ, Wong RJ, Stevenson DK. Photoisomers: obfuscating factors in clinical peroxidase measurements of unbound bilirubin? Pediatrics 2009;123:67-76.
11. Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko J. Hyperbilirubinemia in the newborn infant ≥ 35 weeks' gestation: an update with clarifications. Pediatrics 2009;214(4):1193-1198.
12. Bhutani VK, Johnson LH, Maisels MJ, Newman TB, Phibbs C, Stark AR et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol 2004;24:650-662.
13. Engle WA, Tomashek KM, Committee on Fetus and Newborn. 'Late-preterm' infants: a population at risk. Pediatrics 2007;120:1390-1401.
14. Kaplan M, Renbaum P, Levy-Lahad E, Hammerman C, Lahad A, Beutler E. Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia Proc Natl Acad Sci USA 1997;94:12128-12132.
15. Kaplan M, Beutler E, Vreman HJ, Hammerman C, Levy-Lahad E, Renbaum P et al. Neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes. Pediatrics 1999;104:68-74.
16. Kaplan M, Muraca M, Hammerman C, Rubaltelli FF, Vilei MT, Vreman HJ et al. Imbalance between production and conjugation of bilirubin: a fundamental concept in the mechanism of neonatal jaundice. Pediatrics 2002;11(4):e47.
17. Kaplan M, Hammerman C. The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective. JPerinatol 2009;29(Suppl 1):S46-S52.
18. Newman TB, Liljestrand P, Escobar GJ. Infants with bilirubin levels of 30 mg/dl or more in a large managed care organization. Pediatrics 2003;111(6 Part 1):1303-1311.
19. Harris MC, Bernbaum JC, Polin JR, Zimmerman R, Polin RA. Developmental follow-up of breastfed term and near-term infants with marked hyperbilirubinemia. Pediatrics 2001;107:1075-1080.
20. Hankø E, Lindemann R, Hansen TW. Spectrum of outcome in infants with extreme neonatal jaundice. Acta Paediatr 2001;90(7):782-785.
21. Trikalinos TA, Chung M, Lau J, Ip S. Systematic review of screening for bilirubin encephalopathy in neonates. Pediatrics 2008;124(4):1162-1171.
22. Newman TB, Kuzniewicz MW, Liljestrand P, Wi S, McCulloch C, Escobar GJ. Numbers needed to treat with phototherapy according to American Academy of Pediatrics guidelines. Pediatrics 2009;123(5):1352-1359.
23. Bhutani VK, Johnson LH, Schwoebel A, Gennaro S. A systems approach for neonatal hyperbilirubinemia in term and near-term newborns. J Obstet Gynecol Neonatal Nurs 2006;35:444-455.
24. Eggert LD, Wiedmeier SE, Wilson J, Christensen RD. The effect of instituting a prehospital-discharge newborn bilirubin screening program in an 18-hospital health system. Pediatrics 2006;117: e855-e862.
25. Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med. 2008;358(9):920-928.
26. Newman TB, Xiong B, Gonzales VM, Escobar GJ. Prediction and prevention of extreme neonatal hyperbilirubinemia in a mature health maintenance organization. Arch Pediatr Adolesc Med 2000;154:1140-1147.
27. Escobar GJ, Greene JD, Hulac P, Kincannon E, Bischoff K, Gardner MN et al. Rehospitalization after birth hospitalization : patterns among infants of all gestations. Arch Dis Child 2005;90:125-131.
28. Keren R, Bhutani VK, Luan X, Nihtianova S, Cnaan A, Schwartz SJ. Identifying newborns at risk of significant hyperbilirubinemia. Arch Dis Child 2005;90:415-421.
29. Newman TB, Liljestrand P, Escobar GJ. Combining clinical risk factors with serum bilirubin levels to predict hyperbilirubinemia in newborns. Arch Pediatr Adolesc Med 2005;159:113-119.
30. Keren R, Luan X, Friedman S, Saddlemire S, Cnaan A, Bhutani VK. A comparison of alternative risk-assessment strategies for predicting significant neonatal hyperbilirubinemia in term and near-term infants. Pediatrics 2008;121(1):e170-e179.
31. Johnson LH, Bhutani VK. Guidelines for management of the jaundiced term and nearterm infant. Clin Perinatol 1998;25:555-574.
32. Bhutani VK, Johnson LH, Keren R. Diagnosis and management of hyperbilirubinemia in the term neonate: For a safer first week. Pediatr Clin North Am 2004;51:843-861.
33. Mishra S, Chawla D, Agarwal R, Deorari AK, Paul VK, Bhutani VK. Transcutaneous bilirubinometry reduces need for blood sampling in neonates with visible jaundice. Acta Pediatr. 98(12):1916-1919.
34. Keren R, Luan X, Tremont K, Cnaan A. Visual assessment of jaundice in term and late preterm infants. Arch Dis Child. Fetal Neonatal Ed. 94 (5):F317-F322.
35. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999;103:6-14.
36. Lo SF, Jendrzejczak B, Doumas BT, College of American Pathologists. Laboratory performance in neonatal bilirubin testing using commutable specimens: a progress report on a College of American Pathologists study. Arch Pathol Lab Med 2008;132(11):1781-1785.
37. Ip S, Chung M, Kulig J, O'Brien R, Sege R, Glicken S et al. Subcommittee on hyperbilirubinemia. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics 2004;114: e130-e153.
38. Maisels MJ, Kring E. Transcutaneous bilirubin levels in the first 96 h in a normal newborn population of 35 or more weeks' of gestation. Pediatrics 2006;117:1169-1173.
39. Bhutani V, Gourley GR, Adler S, Kreamer B, Dalman C, Johnson LH. Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess the risk of severe hyperbilirubinemia. Pediatrics 2000;106: e17.
40. Maisels MJ. Transcutaneous bilirubinometry. NeoReviews 2006;7: e217-e225.
41. Bhutani VK, Johnson L. A proposal to prevent severe neonatal hyperbilirubinemia and kernicterus. J Perinatol 2009;29(Suppl 1):S61-S67.
42. Longhurst C, Turner S, Burgos AE. Development of a web-based decision support tool to increase use of neonatal hyperbilirubinemia Guidelines. Jt Comm J Qual Patient Saf 2009;35(5):256-262.
43. Bell R, Bhutani VK, Bollman DL, Nisbet C, Powers R, VanOtterloo L et al. Severe Hyperbilirubinemia Prevention Toolkit. California Perinatal Quality Care Collaborative. http://www.cpqcc.org/.
44. Bhutani VK, Maisels MJ, Stark AR, Buonocore G. Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants X35 weeks gestation. Neonatology 2008;94(1):63-67.
45. Bjerre JV, Petersen JR, Ebbesen F. Surveillance of extreme hyperbilirubinaemia in Denmark. A method to identify the newborn infants. Acta Paediatr 2008;97(8):1030-1034.
46. Bhutani VK, Johnson L. Kernicterus in the 21st century: frequently asked questions. J Perinatol 2009;29(Suppl 1):S20-S24.
47. Mah MP, Clark SL, Akhigbe E, Englebright J, Frye DK, Meyers JA et al. Reduction of severe hyperbilirubinemia following Institution of Universal Predischarge Bilirubin Screening in a Large Private Hospital System. Pediatrics 2010;125: e1143-e1148.
48. Suresh G, Clark R. Cost-effectiveness of strategies that are intended to prevent kernicterus in newborn infants. Pediatrics 2004;114:917-924.
49. Bhutani VK, Johnson L. Kernicterus in late preterm infants cared for as term healthy infants. Semin Perinatol 2006;30(2):89-97.